(OTCMTS: KAST) Kasten Biopharma: Solutions For Serious Conditions Arising in Hospital & Clinical Settings


Headquartered in Silver Springs, Nevada, Kasten Biopharma (OTCMKTS: KAST) is is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals and devices designed to prevent and treat serious conditions arising in the hospital and adjacent clinical settings. The Company is principally focused on delivering solutions to those wards in which the care pathway is burdened by high morbidity, mortality, and cost.


If you know anyone who works in a hospital or elderly care facility, you've surely heard of the acronym "MRSA" (Methicillin-resistant Staphylococcus Aureus.) MRSA is an infection caused by a certain type of Staphylcoccus (staph) bacteria that has become resistant to many of the antibiotics used to treat ordinary staph infections. Most MRSA infections occur in people who are in hospitals or other health care settings, especially nursing homes. MRSA is a highly contagious disease and can be spread through direct contact, door handles, bed sheets, towels, and clothes. GlobalData forecasts that the MRSA treatment market will grow at a compounded annual growth rate of 3.4% over the next few years to reach $3.5 billion by 2019.


Kasten Biopharma (OTCMKTS: KAST) has revealed two major developments at the end of 2016, directing the attention of investors focused on small-cap biopharma companies. First, the reveal of an agreement for the sublicensing of a novel formulation of Bactracin to treat MRSA, and second, the broadening of the company's porfolio though a  definitive agreement with Gulf Coast Pharmaceutical for the treatment of Alzheimer’s Disease and Erectile Dysfunction.

On November 14th, 2016, Kasten, Inc. announced an agreement for the sublicensing of a novel formulation of Bactracin for the treatment of drug resistant bacteria.

At present, the antibiotic topical oitments used to prevent and treat ordinary Staph Infections often contain Bacitracin as an active antimocrobial ingredient. On it's own, Bacitracin is not effective against hyper-resistant MRSA strains such as USA300. New strategies are needed to control emerging resistant pathogenic bacteria.

Image result for bacitracin

Intellectual property has been developed for an antimicrobial formulation that significantly boosts the effectiveness of Bacitracin by using alkyl gallates, a group of antioxidants that are currently used as food preservatives. Bacitracin combined with certain alkyl gallates resulted in an up to 1,000,000-fold increase in bactericidal activity against the hyper resistant MRSA strain USA300. This intellectual property and data has been sublicensed by Kasten Biopharma and will be developed for use for the prevention and treatment of drug resistant bacterial infections.

On December 2nd, 2016, Kasten, Inc. announced a LOI to acquire formulas for Alzheimer's Disease and Erectile Dysfunction. 

                                         Image result for alzheimers

(OTCMKTS: KAST) revealed that they are currently negotiating the terms of the definitive agreement with Gulf Coast Pharmaceutical, Inc. and they are expected to close on the asset purchase within a timely manner.

                                              Image result for erectile dysfunction

 “We are committed to providing solutions to medical conditions to extend quality of life. Alzheimer’s disease is the only leading cause of death in the U.S. that has no therapies to prevent, cure or slow its progression. At $236 billion a year, it is also the most expensive disease in the U.S. We have an opportunity to make a difference for millions of people suffering daily,” stated Jose Delgado, CEO of Kasten, Inc.

(OTCMKTS: KAST) is shaping up to be an exciting biopharma in 2017. We look forward to watching the company progress.

DISCLOSURE: The author is receiving compensation for this article. The views and opinions expressed in this article are those of the authors.. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. TheSultansofSwingTrading receives fees for producing and presenting the Content on this Site along with other media services.  
TAG